| Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma | Clinical Drug Investigation | |
| Gene-Immune Therapy of Cancer: Approaches and Problems | Russian Journal of Genetics | 2022 |
| Novel Therapies in Oncology: An Individualized Approach | AACN Advanced Critical Care | 2021 |
| Challenge of immune-mediated adverse reactions in the emergency department | Emergency Medicine Journal | 2019 |
| Type 1 diabetes mellitus with diabetic ketoacidosis after immune checkpoint inhibitor therapy | Journal of Cancer Research and Practice | 2018 |
| Immune Checkpoint Blockade and Immune Monitoring | | 2018 |
| Missed Druggable Cancer Hallmark: Cancer-Stroma Symbiotic Crosstalk as Paradigm and Hypothesis for Cancer Therapy | BioEssays | 2018 |
| From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift? | Current Oncology Reports | 2018 |
| Biologicals: spectrum en targets | Bijblijven (Amsterdam, Netherlands) | 2018 |
| Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group | | 2017 |
| Management and Supportive Care of Patients Undergoing Immunotherapy | | 2017 |
| Supportive care for patients undergoing immunotherapy | Supportive Care in Cancer | 2017 |
| Checkpoint Inhibitors: Applications for Autoimmunity | Current Allergy and Asthma Reports | 2017 |
| [The pathology of adverse events with immune checkpoint inhibitors] | Der Pathologe | 2017 |
